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ABSTRACT 
Background: 
Low adherence to cardiac rehabilitation (CR) might be improved by remote monitoring 
systems that can be used to motivate and supervise patients and tailor CR safely and 
effectively to their needs. The main objective of this study was to evaluate the feasibility of a 
smartphone guided training system (GEX) and whether it could improve exercise capacity 
compared to CR delivered by conventional methods for patients with coronary artery 
disease (CAD). 
Design: 
A prospective, randomized, international, multi-center-study comparing CR delivered by 
conventional means (CG) or by remote monitoring (IG) using a new training 
steering/feedback tool (GEx System). This consisted of a sensor monitoring breathing rate 
and the electrocardiogram that transmitted information on training intensity, arrhythmias 
and adherence to training prescriptions, wirelessly via the internet, to a medical team that 
provided feedback and adjusted training prescriptions. Exercise capacity was evaluated prior 
to and six months after intervention.  
Results:  
118 patients (58±10 years, 105 men) with CAD referred for CR were randomized (IG: n=55, 
CG: n=63). However, 15 patients (27%) in the IG and 18 (29%) in the CG withdrew 
participation and technical problems prevented a further 21 patients (38%) in the IG from 
participating. No training related complications occurred. For those who completed the 
study, peak VO2 improved more (p=0.005) in the IG (1.76±4.1ml/min/kg) compared to CG (-
0.4±2.7ml/min/kg).  
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Conclusion:  
A newly designed system for home-based CR appears feasible, safe and improves exercise 
capacity compared to national CR. Technical problems reflected the complexity of applying 
remote monitoring solutions at an international level.  
Key Words: Exercise training, cardiac rehabilitation, monitoring 
 
a. ABBREVIATIONS 
 BF  Breathing frequency  
 BP  Blood pressure 
CAD   Coronary artery disease 
CG  Control group 
CPX  Cardiac exercise testing 
 CR  Cardiac rehabilitation  
CTC   Central Training Committee 
dO2/HR aerobic workrate 
 EF  Ejection fraction 
 GEx  Guided Exercise 
 HF  Heart failure 
 HR  Heart rate 
 HRR  Heart rate reserve  
 IG  Intervention group 
 MI  Myocardial infarction 
 O2/HR  oxygen pulse 
 PC  Personal Computer 
 QoL  Quality of life 
VO2peak Peak oxygen uptake 
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b. INTRODUCTION 
Cardiac rehabilitation (CR) aims at restoring exercise performance [1] in patients after 
a cardiac event like myocardial infarction (MI) [1], peripheral arterial disease [2,3] or heart 
failure (HF).[3-7] CR uses multifactorial intervention, including aggressive risk factor 
modification [8-11,7]. Traditionally, these programs have tried to improve physical health 
and individual attitude through exercise-only based CR or comprehensive CR (e.g. smoking 
cessation, dietary counseling as well as exercise).[8] Meta-analyses on exercise based CR 
showed a significant reduction in cardiac mortality of about 27% compared to patients 
receiving conventional care.[9],[12] Still, there are relevant national differences in how CR 
programs are organized.[9] Unfortunately, despite efficacy and cost-effectiveness CR, is 
pursued by less than one-third of eligible patients.[13] As beneficial effects of CR largely 
depend on continuation of a lifetime exercise program after a structured CR, patients should 
be encouraged to continue with an individual exercise program to preserve an improvement 
in exercise capacity. [8,10,11,13-18] 
Reasons for non-participation in CR included unavailability of hospital-based CR, lack 
of motivation or other reasons e.g. excessive travel distance [19] Quality performance 
criteria, automated referral systems and options for home-based CR services may increase 
adherence to therapies in some patients. Besides centre-based CR, home-based CR offers a 
potentially valuable alternative for many individuals [20-22], and has proved to introduce 
similar improvements compared to center-based programs across a range of measures [23] 
at lower [24] or comparable cost.  
These findings would support an extension of home-based CR as an attempt to widen 
access and participation.[25-27] Furthermore, the evolution of the technology has led to the 
design of mobile-based solutions which could facilitate home based CR and overcome 
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patient safety concerns.[28-32] The GEx system [33-35], designed under those requirements, 
introduces a closed-loop disease management system supporting the prescription and 
administration of CR. A feasibility study was previously performed to compare signals of this 
new system with standard cardiac exercise testing (CPX) during inpatient phase-II-CR that 
showed the suitability of the whole system for monitoring of home-based CR [36] with 
accurate heart rate (HR) measurements. In this present study improvements obtained due to 
long-term home-based CR (CR- phase III) were determined. Guided exercise training 
supervised by the GEx system was compared to the standard care in three different 
countries (Great Britain, Spain, Germany). 
 
c. METHODS 
Study design and study objectives, ethical considerations 
In this open, prospective, randomized, parallel group, German, British and Spanish, three-
center, Phase I study, the standard national approach to CR was compared to an approach 
adding the new training steering and feed-back GEx System. All patients were recruited 
during phase II cardiac rehabilitation in Spain, GB and Germany to compare national 
difference in CR. The study was performed after discharge from rehabilitation facilities at 
home (phase III rehabilitation) with individual training prescription. Patients were 
randomized to an intervention group (IG) and a control group (CG). Overall, treatment was 
according to national CR recommendations. Additionally, patients randomized to the IG 
were equipped with the GEx System. 
The main objective of this study was to evaluate, whether the GEx System can 
improve physical exercise capacity at 6 months follow up during home based, phase III CR  
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compared to national CR standards. Secondary objectives were to evaluate the effect of the 
GEx System on compliance, total exercise time, fear and anxiety, physical fitness, symptoms 
and whether home training was safe as well as serum cholesterol, LDL and  fastening 
glucoses blood pressure (BP) control, QoL and ejection fraction (EF) .  
The Regional Ethical Review Board at the University of Aachen (00017326, EK218/11), 
Hospital Clínico San Carlos of Madrid (C.I. 11/232-E) and University of Hull (12/YH/0072) 
approved the study. Principles according to the Helsinki declaration (WMA 2008) were 
followed. Written informed consent was obtained from all participants prior to inclusion in 
the study. Also, the study was registered at ClinicalTrials.gov (identifier NCT01761448). 
 
Inclusion and exclusion criteria 
 Inclusion criteria were: presence of CAD after acute MI or elective coronary 
intervention, EF > 30%, willing to exercise, eligible for CR and ability to use computer and 
Internet. Respectively, exclusion criteria were: EF < 30%, HF with NYHA IV, inability to 
exercise, severe valve disease, recent cardiac surgery < 4 weeks, implantable devices (ICD or 
CRT-device, pacemaker) or open thorax wound. 
 
Study phases and data acquisition 
All patients underwent an initial baseline evaluation consisting of a careful history 
taking (with activity profile evaluation) and a physical examination. A standard ECG, 
laboratory analysis, 2D echocardiography and exercise testing with additional lactate 
samples was carried out. All individuals were asked to fill in QoL questionnaires.  
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During the 6-month training phase, patients in the IG performed training under 
guidance of the GEx system. Individual training performance was closely monitored and 
exercise prescriptions were continuously reviewed and adjusted as needed. This was done 
by a dedicated team of sport physicians and exercise scientists, the so-called Central Training 
Committee (CTC). Patients in the IG were evaluated with respect to usability of the system, 
knowledge about heart-related health, exercise habits and adaption efforts. In contrast, 
patients in the CG were asked to report on daily physical activities on a paper dairy.  
At 6 month FU, all baseline examinations were repeated in both groups.  
 
Laboratory parameters 
Urea clearance, potassium, sodium, white/red blood cell count, platelet count, total 
cholesterol, LDL- cholesterol, HDL, Cholesterol, HbA1c, hsCRP, ntBNP were analyzed. 
 
ECG 
A standard electrocardiography was performed using a commercial system at each 
site.  
 
Echocardiography 
A standard 2D-echocardiography was performed using available systems at the 
different sites. All standard views (2 and 4-chamber view) were acquired. Left ventricular EF 
was then calculated according to Simpson’s method.  
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Quality of life 
All patients were instructed to complete questionnaires regarding QoL (EQ5D)[37] 
and anxiety and depression (HADS)[38]. 
 
Cardiopulmonary exercise testing (CPX) 
A cardiopulmonary exercise testing (cycle ergometer) starting at 25 W, with 
increments of 25 W per 2 minutes (incremental), was performed. Peak oxygen uptake 
(VO2peak) at peak exercise was defined as the highest oxygen consumption measured during 
the last 30 s of the symptom-limited exercise test and expressed as ml/kg/min. VO2 (ml/ 
kg/min), VCO2 (L/min), and VE (L/min) were collected throughout the test. VE and VCO2 
were designated as the y- and x-axis variables, respectively. VE/ CO2 slope was calculated 
with the slope calculation option of the software package. In Aachen Carefusion 
Masterscreen CPX, Lab Manager Version 4.67 was used, in Hull Innocor by Innovision and in 
Spain Ergostik Geratherm were applied. HR was taken through 12 lead ECG. BP was taken 
using an automated BP machine with integrated microphone (Getemed). During testing, 
relevant ischemia, arrhythmias, HR and BP were evaluated. For anaerobic threshold v-slope  
method was used. [39,40]. Also HR reserve (HRR, normal < 20 bpm), oxygen pulse (O2/HR, 
ml/beat) and aerobic workrate dO2/dW (normal > 10 ml/min/W) [41,42] were determined. 
Lactate concentration was measured at baseline and at every exercise step. 
Specifically, HR and watt at 2mmol lactate and at 4mmol lactate were obtained.  
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Guided Exercise System (GEx) 
The GEx system is a closed-loop disease management system facilitating prescription 
and administration of CR therapies[36] made up of three main components: Professional 
System, Patient Station and Portable Station.  
 The Professional System is a web-based tool for medical professionals (Figure 2) 
providing information on the patients’ profile with respect to medical history and CR 
prescription and performance in the past. Furthermore, data from the patients’ systems 
(Portable Station and Patient Station) including HR, BP, notifications on events during 
exercise session and ECG tracings are displayed.  
 The Patient Station acts as the gateway between the Portable Station and the 
Professional System, as it is able to synchronize exercise plans prescribed by professionals 
and extract monitored data from the portable station and upload them to the professional 
system. It is also in charge of providing educational material and motivational feedback 
generated from actual exercise performances. 
 The Portable Station (Figure 1) is used by the patient during prescribed exercise 
sessions. It includes a sensor for acquisition of vital signs and a smart-phone for interaction 
with patients. The smart-phone software contains algorithms that process the vitals 
collected from the sensor and, based on the individual exercise plan, provide immediate 
feedback with respect to training intensity (Figure 2). 
In order to ensure patients’ safety and to avoid hazardous situations, a series of 
verifications were implemented prior to each CR session (cardiac symptoms (angina pectoris, 
dyspnea), well-being, blood pressure). Patients received immediate feedback on whether it 
was safe to exercise or if it was better to reschedule the exercise at a later point in time.  
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Training prescription/ Central Training Committee (CTC) 
The CTC was created to obtain individual training prescription for all patients at all 
trial sites based on a homogeneous strategy. The information gathered during initial exercise 
testing was sent to the Institute for Cardiology and Sports Medicine, German Sports 
University Cologne, Germany for all patients. This held also true for retesting performed 
during the training phase. At the CTC, individual exercise prescriptions for each patient 
participating in IG of the study were elaborated and sent back to the study site. Importantly, 
all changes in medication, especially beta-blockers and calcium channel blockers had to be 
announced to the training committee.  
In case a patient failed to follow the training prescription or was at risk of over-
exercising, the CTC had to be notified to assess whether a change in the training prescription 
was needed. 
 
Description of training content 
Patients were instructed to perform training sessions containing endurance but also 
resistance training. The goal of the endurance training (e.g. cycling, walking) was to make the 
patient work out in a safe but also effective HR zone. Consequently, patients’ HR was 
supposed to stay in an individual, pre-defined target zone. [43] 
Resistance training was a combination of both isometric and isotonic exercises using 
a rubber band. 
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Intensification strategy 
The intensification strategy followed the FITT [44,45] (frequency, intensity, time and 
type of activity) principles model. GEx patients indeed followed a training plan consisting on 
three stages as described in Figure 3. 
 
Power calculation, randomization and statistical analysis 
According to previous literature [46,47], it is feasible to expect a 3 ml/min/kg 
standard deviation of the main variable (VO2max). A sample size of 130 analyzable patients 
(65 per group) would therefore have adequate power (80%) at a 5% level of significance 
(one-tailed) to show a 1,3 ml/min/kg difference. In order to meet the minimum sample size 
requirements for the objectives, accounting for possible study attrition (e.g. subject death, 
withdraw of consent), the study was meant to enroll a total of 150 subjects. More 
specifically, 25 patients per group were expected for each study site, thus, 50 patients were 
meant to be included at each site. Overall, 75 patients for each randomization group had to 
be allocated. All analyses of secondary endpoints were regarded as exploratory. The 
explorative approach were concomitant the explanation not to adjust for multiple 
comparisons. The p-values were therefore merely descriptive.  
All data were stored in an eCRF using the number of randomized patient as 
identification.  
Randomization stratified by ‘gender’ and ‘centre’ was done electronically by the 
system (eCRF). To evaluate the number of patients that matched with the inclusion and 
exclusion criteria, a screening list was carried. Due to the kind of intervention, the study had 
to be performed open-labeled. The un-blinded design seemed to be appropriate to reach 
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primary objectives. However, physicians/technicians performing and evaluating 
echocardiography or functional testing were unaware of the study group.  
Continuous data was summarized by the median (interquartile range); categorical 
data by percentages. A two-tailed Student's t test was used for comparison between groups. 
Linear regression was used to adjust for baseline covariates (age and sex as a minimum). 
Residuals were checked for normality. Either Fisher's exact test or Chi-squared test were 
used for categorical variables with nominal scales and the Mann-Whitney U test for 
categorical variables with ordinal scales. Missing values were not imputed but reported in 
Tables. All tests were assessed at the 5% statistical significance level. The ‘Stata’ statistical 
computer package was used to analyze the data. 
 
d. RESULTS 
Patients’ characteristics 
Starting on 4/2011, 132 patients (59 ± 14 years, 11 % females) gave consent (33 in 
Aachen, Germany, 44 in Hull, GB and 55 in Madrid, Spain). Of these, 89 % were randomized 
and included in the study: 63/53% were assigned to the CG and 55/47% to the IG (table 1).  
The patients’ characteristics are stated in Table 2. Patients were recruited during the phase II 
rehabilitation. This allowed all patients to enter the study at the same stage, thus, delivering 
the same information to all patients at the same point in time. Furthermore, the phase II 
could be used to make patients familiar with the new training tool and provide time for 
further instructions.  
All patients were on standard medication for CAD (table 2). Table 2 shows the 
baseline exercise characteristics of the patients consented. Furthermore quality of life 
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characteristics at the beginning of the study are stated in table 2, showing no difference 
between anxiety, depression and EQ-5D at baseline.  
 
Randomization and follow-up  
In the IG, 15 patients (27%) dropped out before starting the guided rehabilitation. Of 
those actually participating in the program 12(30%) finished all interventions. However, 
17(8%) showed poor compliance and 21 patients (53%) stopped during the training phase 
due to several reasons: lack of time, issues with Internet connectivity, demotivation because 
of safety algorithms delaying or stopping  exercise too often, follow up was already too late, 
or no training was allowed due to chronic infections or chronic back pain.  
In the CG, n=15 patients denied participation in the study and n=3 patients cancelled 
follow-up investigations. 
 
Training sessions and safety algorithm 
In effect, only 43% of the exercise sessions were fully completed, other 37% were 
interrupted by the safety algorithms, 20% where abandoned because of technical errors (e.g. 
poor signal quality or poor communication with sensor), and 2% were explicitly stopped by 
the users. 
This may explain why some users got annoyed by the safety measurements. More 
concretely, of these interruptions, 63% were because of high BP,  26% because of HR values 
out of range for too long and the remaining 2% because of other reported symptoms. 
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Safety of cardiac rehabilitation 
Adverse events were reported in 6 patients (31%) in the IG and 3 patients (8%) in the 
CG. However, there was no complication directly associated with CR. More specifically, in 
the IG 2 patients complained of chest pain based on chest infection after CABG, 2 patients 
were admitted to hospital with consecutive angiography due to new onset of angina pectoris 
which was not related to training and 2 patients contacted the study center because of chest 
pain before training and were sent to hospital for further investigation resulting in CABG 
because of progression of disease. In the CG, reasons for adverse event were new onset of 
atrial fibrillation (n=1), new angina at rest (n=1), which resulted in angiography without 
intervention and pseudo aneurysm of the right femoral arteries after PCI (n=1) with surgery 
intervention. 
 
Outcome of the primary endpoint 
If compared between CG and IG, the use of the GEx system results in a statistically 
higher improvement in VO2peak (Table 3).  
In both groups, CR resulted in reduction of HR at rest and at anaerobic threshold, 
reduction of VE/VCO2-slope, increased maximum watts, reduction of lactate levels at 4, 6, 8 
and 10 minutes during exercise. However, there was no significant difference with respect to 
increase in the latter parameters between the two groups.  
 
Outcome of the secondary endpoints 
Clinical parameters 
BMI in the CG and IG showed no significant reduction. (Table 3). 
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Echocardiography parameters 
Additionally, training in the CG group showed a significant decrease in EF, whereas in 
the IG group the EF was increased. Also, the there was a significant difference between the 
group regarding change in EF (p=0.004) (Table 3).  
 
Laboratory parameters 
Training results in both groups in a non-significant reduction of total cholesterol, LDL 
and fastening glucose, reduction of hsCRP and nT-pro-BNP-levels (Table 7). Statistically, 
there was no significant difference between the two groups (Table 4)  
 
Quality of life 
Comparison of anxiety and depression and EQ-5D showed no significant difference 
between CG and IG (Table 5). 
 
e. DISCUSSION 
The main finding of this study is that home CR was feasible and safe. Furthermore, it 
seems that adequate use of the GEx system had a substantial effect on exercise capacity 
compared to standard CR in patients with cardiac disease.  
Unexpectedly, some problems were encountered with the safety mechanism 
implemented in the portable device, which completely prevented patient participation or 
caused frequent delays leading to patient frustration and de-motivation. There may be 
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several reasons for it: patients started exercising with too high intensity during the warm-up 
or the target HR limit was so low during warm-up that it was difficult to keep HR there.  
Several sessions were cancelled or delayed also because of the safety measures used with BP 
values. That safety mechanism included research algorithms that had not been extensively 
tested with CAD patients and therefore were not optimized. An important note for the 
future is that the target HR zone should be wide enough so that the user is able to keep HR 
within the target and BP safety thresholds should be better tailored to patient’s conditions. 
These issues would have been readily surmountable had a prototype safety algorithm been 
clinically tested in advance with a sufficient number of patients or had there been more time 
to conduct the study.  
Although there were technical problems, the system was accepted by users as also 
confirmed by a specific acceptance questionnaire. 
In conclusions, for those patients who were not affected by the security algorithms, 
quality of the HR signal was good and the patients were able to keep their HR within the 
prescribed HR zone. 
 
f. LIMITATIONS 
Due to some technical problems and the strict behavior in the safety mechanisms, 
only a limited number of patients were able to reach the final study point. Still, the GEx 
Study demonstrated a considerable improvement in cardio-pulmonary performance with a 
remotely supported training program compared to standard CR. Indeed, the magnitude of 
effect appeared substantially greater than with other exercise training programs that 
depend on patients attending classes and complying with exercise prescriptions at home, 
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between classes, without remote support. The number of dropouts was disappointing but 
does not detract from remotely supported rehabilitation as a proof of concept. Some 
technical issues can be fixed, more lax safety algorithm can be implemented and the 
methods and implementation of the exercise prescription can certainly be improved. This 
trial provides the impetus to scale up the intervention to manage much larger patient 
groups, potentially in the context of further randomized controlled trials. 
g. CONCLUSION 
The GEx system for home based CR showed to be feasible and successful as compared 
to three different national CR systems (GB, Spain, Germany). It improved exercise capacity, 
was associated with reduction of weight, levels of hsCRP and cholesterol-levels. Training 
sessions were safely performed. Still, a more mature technological solution is required to 
make it an alternative for today’s standard CR approach.  
 Unfortunately the major loss to follow-up weakens any conclusions that can be 
drawn from the study. However, the study could be viewed as an important proof-of-
concept that can be refined for deployment in more substantial clinical trials.   
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m. FIGURE ANNOTATIONS 
 
Figure 1:  Components of the portable station a) ECG-Sensor, b) west c) PDA attached to the 
arm d) PDA for training 
 
Figure 2: Web based training database 
Web based training data base. A status bar on the bottom of the screen where 
specific information about the logged user is displayed: 
User name, Status message on the actions the user performs in the system,  
Language selection. Patients training data is visible and progress of training process.  
 
Figure 3: Cardiac exercise program 
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Site Cons
ente
d 
Study 
Group 
Randomi
zed 
Started 
Intervent
ion 
Dropped Out 
after 
Starting 
Poor 
Compli
ance 
Final 
Test 
Done
*1 
Germany 33 C 18  2  10 
I 14 12 4 1 8 
Spain 55 C 25  10  15 
I 17 4 3 1 1 
UK 44 C 20  3  17 
I 24 24 14 5 3 
Total 132 C 63  18  42 
I 55 40 21  7 12 
 
Table 1: Inclusion of patients 
 
 
 
  
                                                          
1 Includes patients with poor compliance: <50% of expected training sessions 
Table
  
 
 
Table 2:  Patient characteristics at baseline  
Variable Missing Control (n=63) Intervention 
(n=55) 
    
Age (years)  58(52,67) 60(50,65) 
Sex (men)                               55(87%) 50(91%) 
BMI(Kg/m2)    27.7(25.1,30.8)         28.4(25.3,32) 
SBP(mmHg)                               130(113,140) 129(120,140) 
DBP(mmHg)    77(70,83)               80(72,87) 
Total cholesterol(mmol/L) 20 139(123,165) 154(136,180) 
Glucose(mg/dl)                 12 100.9(86,115) 97(88.2,132) 
NTproBNP(ng/l) 16 194(83,498) 209(71,721) 
Ejection fraction(%) 5 61(57,70) 56(50,65) 
ACE-Inhibitors (n,%) 0 32 (50) 33 (58) 
ARB  (n,%) 0 17 (26) 13 (23) 
Aspirin (n,%) 0 55 (85) 52 (92) 
Betablockers (n,%) 0 54 (84) 44 (78) 
Calciumchannelblockers 
(n,%) 
0 4 (6) 6 (11) 
Diuretics (n,%) 0 8 (13) 12 (21) 
Nitrates (n,%) 0 10 (16) 21 (37) 
Statins (n,%) 0 58 (90) 53 (94) 
Spironolactone (n,%) 0 1 (2) 1 (2) 
Exercise time(min) 12 8(8,10) 8(8,10) 
Maximum Watts(W) 4 125(100,150) 125(100,150) 
Resting HR(bpm)            10 71.7 (44,103)             72 (46,107) 
VO2(ml/min/Kg)  AT           10 12.8(11.7,15.9)         13.8(10.9,16.7) 
Peak VO2(ml/min/Kg) 30 20(17,23) 21.5(17.2,24.8) 
O2 (ml/beat) 5 13.3(11,15.5) 12.6(10.9,15.8) 
dO2/dW (ml/min/W) 4 10.1(8.9,11.8) 10.3(8.7,11.3) 
VEV/CO2 ratio              13 32.5(28.2,36) 33.5(29.7,42) 
HRR (bpm) 4 50(38,63) 47(37,64) 
HADS anxiety   (Points)               26    20(17,21)      19(18,21) 
HADS depression   
(Points)         
   26    16(15,17)      16(15,16) 
EQ-5D (Points)    10    70(60,85)      80(70,90) 
 
Notes. Data shown are median (25th/75th centiles) or n(%).BMI=body mass index.  
SBP=systolic blood pressure. DBP=diastolic blood pressure. HR=heart rate.  
 
  
 
M
V 
End 
of 
Study 
Contr
ol 
Grou
p 
P 
(versus 
Baselin
e) 
M
V 
End of 
study 
Interventio
nal group 
P 
(versus 
baselin
e) 
Delta 
Contr
ol 
group 
Delta  
Interventio
nal group 
P (delta 
control vs. 
delta 
interventio
nal) 
N=  42   19  42 19  
Maximu
m Watts 
(W) 
0 118.4 
± 35 
0.78 0 126 ± 47 0.95 4.6 ± 
35 
11.6 ± 15 0.32 
Exercise 
Time 
(min) 
12 8.1 
±1.9 
0.77 1 8.4 ±1.7 0.88 -
0.13± 
1.6 
0.71± 1.2 0.053 
Resting 
HR (bpm) 
0 64± 
10 
* 0.004 0 64 ±10 *0.007 -5.9 
±10.7 
-18± 7.8 0.1 
HR AT 
(bpm) 
0 96 
±12 
* 0.03 0 105 ±20 0.72 -6.7 
±21 
-0.9± 16 0.27 
Maximu
m HR 
(bpm) 
0 117 
±21.4 
0.21 0 127 ±21 0.86 -4 ± 
22 
1 ±10 0.15 
Systolic 
RR at rest 
(mm HG) 
0 124 
±16 
0.14 0 139 ±19 0.09 -8 
±12 
6 ±16 
*0.003 
Diastolic 
RR at rest 
(mm Hg) 
0 72.6 
±9.5 
* 0.03 0 83±7 0.32 -5 ±9 1.8 ±9 
*0.01 
VO2 AT 
(ml/min/
kg) 
0 16.6 
±12.7 
0.11 0 17.4 ±8.1 0.09 2.5± 
13.2 
2.4 ±2.5 0.97 
VO2 peak 
(ml/min/
kg) 
0 19.5 
±4.8 
0.75 0 21.9 ±8.3 0.42 -0.4 
±2.7  
1.76± 4.1 
*0.005 
O2/HR 
(ml/beat) 
0 13.6 
±3.1 
0.81 0 15.1 ±5.2 0.27 0.01± 
3.1 
1.6 ±3.3 0.08 
dO2/HR 
(ml/min/
W) 
0 10.2 
±2.1 
0.78 0 10.6 ±3.1 0.49 0.06 
±1.7 
1.32± 3.5 0.18 
VE/VCO2-
slope 
0 30.9 
±5.1 
0.28 0 30.8 ±5.7 0.08 -1.56 
±5.3 
-4.2 ±5 0.09 
HRR 
(bpm) 
0 55 
±20.6 
0.29 0 64.3 ±24.8 0.06 3.5± 
14.7 
3.1 ±13.7 0.89 
Lactate at 
2 min 
(mmol) 
1 1.5 
±0.9 
0.17 2 1.3 ±0.35 0.051 -0.24 
±0.9 
-0.32± 0.9 0.77 
Lactate at 
4 min 
(mmol) 
1 1.9 ±1 0.07 2 1.7 ±0.67 *0.02 -0.2± 
0.5 
-0.46 ±1.1 0.39 
Lactate at 1 2.6 * 0.02 2 2.3 ±0.8 *0.02 -0.4± -0.97± 1.4 0.17 
6 min 
(mmol) 
±1.5 0.8 
Lactate at 
8 min 
(mmol) 
1 3.2 
±2.2 
* 0.01  2 3.3 ±1.4 *0.03 -
0.98± 
1.3 
-0.5 ±0.38 0.15 
Lactate at 
10 min 
(mmol) 
1 3.8 
±1.4 
0.12 2 3.2 ±1.6 *0.03 -1.3 
±0.7 
-0.96 ±0.5 0.23 
EF (%)  2 55±9 * 0.001 0 60 ±10 0.18 -5±8 2±10 *0.004 
Exercise Variables and EF 
Table 3.  Exercise characteristics of control group and interventional group  at the end of the study 
period, mean  ± SD, *:p < 0.05 paired or unpaired t-test/Mann-Whiney U-Test  
  
 Variable M
V 
End 
of 
Study 
Contr
ol 
Grou
p 
P 
(versus 
Baselin
e) 
M
V 
End of 
study 
Interventio
nal group 
P 
(versus 
baselin
e) 
Delta 
Contr
ol 
group 
Delta  
Interventio
nal group 
P (delta 
control vs. 
delta 
interventio
nal) 
N=  42   19  42 19  
Total 
choleste
rol 
(mmol/l) 
3 149.2 
±33.7 
0.96 1 151.8 ±40 0.48 3.3 
±26.5 
-0.38± 27.4 0.64 
LDL-
choleste
rol 
(mmol/l) 
5 77.5 
±25.8 
0.3 3 77.5  ±31.7 0.63 -10.5 
±64 
-2.4± 26.2 0.57 
HDL-
choleste
rol 
(mmol/l) 
6 42.9 
±10.2 
0.13 1 47.9 ±15.9 0.27 4.3 
±11 
6.14 ±7.46 0.55 
Fastenin
g 
glucose 
(mg/dl) 
8 98.6 
±44 
0.1 4 104.7 ±22.3 0.38 -24 
±103 
6 ±20.1 0.11 
hsCRP 
(mg/dl) 
2 1.67 
±1.4 
0.19 7 2.3 ±5.1 0.32 -1.3± 
2.8 
-0.98 ±1.8 0.71 
NT-
proBNP 
(ng/l) 
2 256.8 
±349 
0.36 4 289.8± 408 0.31 -
153.5 
±382 
-232 ±485 0.59 
BMI 
(kg/m2) 
0 28.2 
±3.2 
0.65 0 27.3 ±4.5 0.17 -0.2± 
0.7 
-0.37 ±1.1 0.56 
Table 4: Blood parameters and BMI at the end oft he study period, comparision between CG and 
IG, mean  ± SD, p < 0.05 paired or unpaired t-test/Mann-Whiney U-Test  
  
  
Variable M
V 
End of 
Study 
Contr
ol 
Group 
P 
(vers
us 
Begin
) 
M
V 
End of 
study 
Interventio
nal group 
P 
(vers
us 
begin
) 
Delta 
Contr
ol 
group 
Delta  
Interventio
nal group 
P (delta 
control vs. 
delta 
intervention
al) 
N=  42   19  42 19  
EQ-5D 
(Poinzt) 
0 74.5 
±12.9 
0.41 0 76.3 ±15 0.88 0.54± 
10.7 
0.64 ±13.9 0.98 
HADS-
Anxiety 
(Points) 
 19.2 
±3.2 
0.8  19.3 ±1.9 0.51 -0.63 
±3.8 
1.6 ±3.1 0.1 
HADS-
Depressi
on 
(Points) 
 15.6± 
1.8 
0.37  15.6 ±1.1 0.64 0 ±1.6 1.36± 3.7 0.27 
Table 5: QoL-indices at the end oft he study period, comparision between CG and IG 
All mean  ± SD, p < 0.05 paired or unpaired t-test/Mann-Whiney U-Test, MV: missing value 
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